{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-108155","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2022-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.631343+00:00","generated_at":"2026-06-26T06:54:51.186896+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Vaxcyte enters manufacturing pact with Lonza for pneumococcal vaccine","bullets":["Master Services Agreement effective March 22, 2022 for clinical manufacturing of Vaxcyte's PCV.","Initial term of five years; either party may terminate for material breach, insolvency, or convenience.","Vaxcyte owns IP directly derivative of its product; Lonza owns generally applicable IP or improvements to Lonza background.","No financial terms disclosed; Lonza paid for services, pass-through costs, and a procurement fee."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-108155","json":"https://secwatch.observer/filing/0001193125-22-108155.json","markdown":"https://secwatch.observer/filing/0001193125-22-108155.md","text":"https://secwatch.observer/filing/0001193125-22-108155.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000119312522108155/0001193125-22-108155-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000119312522108155/d292140d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T06:54:51.186896+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}